SCHEMBL7085577

SCHEMBL7085577

COc1ccc(C(=O)C(=O)c2cccc(-c3cc(C)cs3)c2-c2ccccc2)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.49
CES1 P23141 1/20 0.49
TNFRSF1A P19438 3/20 0.47
MAPT P10636 4/20 0.42
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 3/20 0.42
HPGD P15428 2/20 0.42
GAA P10253 2/20 0.42
HTT P42858 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
LMNA P02545 1/20 0.41
CHEK1 O14757 1/20 0.39
PIM1 P11309 1/20 0.39
MAPK8 P45983 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
CTNNB1 P35222 1/20 0.39
WNT3A P56704 1/20 0.39
KMT2A Q03164 2/20 0.39
MAPK1 P28482 2/20 0.39
CA12 O43570 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7089403 0.93 ADORA3 (0.45) CES2CES1TNFRSF1AMAPTKDM4E
SCHEMBL7091527 0.84 TNFRSF1A (0.36) TNFRSF1AKDM4EALDH1A1HPGDGAA
SCHEMBL7090554 0.84 NPSR1 (0.37) CES2CES1MAPTKDM4EALDH1A1
SCHEMBL7133865 0.81 RAB9A (0.46) CES2CES1MAPTKDM4EALDH1A1
SCHEMBL7085135 0.81 TNF (0.39) TNFRSF1AMAPTKDM4EALDH1A1HPGD
SCHEMBL7090550 0.77 AKR1C3 (0.37) TNFRSF1AMAPTKDM4EALDH1A1HPGD
SCHEMBL7084272 0.76 CES2 (0.50) CES2CES1LMNA
SCHEMBL7090216 0.72 CTSA (0.36) TNFRSF1AHTTKMT2AUSP2MEN1
SCHEMBL7088052 0.72 RXFP1 (0.35) CES2CES1MAPTKDM4EALDH1A1
SCHEMBL11333761 0.71 CES2 (0.71) CES2CES1TNFRSF1AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation G.D. SEARLE & CO. 2003-03-13 US disclosed
EP-0772601-B1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-18 EP disclosed
US-6426360-B1 ANTIARTHRITIC AGENTS G D SEARLE & CO. 2002-07-30 US disclosed
WO-1996003387-A1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation AHR, HACL2, IRAK2 CES2 984/4885CES1 374/4885TNFRSF1A 2663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.